Understanding Telix, page-239

and from The Australian:

Telix Pharmaceuticals (ASX:TLX)IFM Investors’ executive director, Rikki Bannan, has tipped ASX listed cancer diagnostics company, Telix Pharmaceuticals, for her Sohn stock market tip.Bannan, a portfolio manager in small caps fund run by the $215bn IFM Investors’ group, said the company which was listed on the ASX in 2017 was significantly undervalued with investors not appreciating the products in its development pipeline.She said the stock, which is owned by IFM, which is currently selling at around $9 a share, should be worth as much as $16 a share if its future products are properly valued, particularly in the area of renal cancer diagnostics in the US market.The company is a commercial-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products using targeted radiation.The company has received global regulatory approvals from the Australian Therapeutic Goods Administration (TGA), the US Food and Drug Administration (FDA), and Health Canada for its prostate cancer imaging agent and has more than 20 clinical trials underway worldwide.